Juergen Siekmann

This inventor holds 45 USPTO granted patents and 26 published patent applications, plus 10 CIPO patents and 17 EPO patents, primarily in Protein Conjugation. Top assignees: Baxter International Inc., Baxter Healthcare Sa, Baxalta Gmbh. Active years: 2000-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Juergen Siekmann. Retrieved from https://idiyas.com/inventor/juergen-siekmann

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 45 (Patent Applications = 26)

% Patents Active = 97.8

CIPO Patents = 10 (Patent Applications = 4)

EPO Patents = 17 (Patent Applications = 26)

Average Co-Inventor Count = 3.2

ph-index = 7

Forward Citations = 209(Granted Patents)

Company Filing History:

29 out of 2,533

Baxter International Inc.

Takeda Pharmaceutical Company Limited

Baxter Aktiengesellschaft

patents

7. 2 out of 57

Lipoxen Technologies Incorporated

patents

8. 1 out of 24

Baxter Healthcare Inc.

patents

where one patent can have more than one assignee

Years Active: 2000-2026

Loading Chart...

Areas of Expertise:

Therapeutic Proteins

Nucleophilic Catalysts

Blood Coagulation

Polymer Conjugates

Factor VIII

Glycopolysialylation

Detection Methods

Hydrolysable Linkers

Fmoc-based Linkers

Physiologically Acceptable Polymers

Antibody Detection

Von Willebrand Factor

45 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12553842 - Determination of modification degree of therapeutic proteins using 1H-NMR spectroscopy (2026-02-17),

2. 11564992 - Nucleophilic catalysts for oxime linkage (2023-01-31),

3. 11040109 - Blood coagulation protein conjugates (2021-06-22),

4. 11020458 - Factor VIII polymer conjugates (2021-06-01),

5. 10772968 - Glycopolysialylation of non-blood coagulation proteins (2020-09-15),

6. 10576160 - Nucleophilic catalysts for oxime linkage (2020-03-03),

7. 10414793 - Nucleophilic catalysts for oxime linkage (2019-09-17),

8. 10350301 - Blood coagulation protein conjugates (2019-07-16),

9. 10251941 - Factor VIIa-polysialic acid conjugates having prolonged in vivo half-life (2019-04-09),

10. 9795683 - Glycopolysialylation of non-blood coagulation proteins (2017-10-24),

11. 9731024 - Nucleophilic catalysts for oxime linkage (2017-08-15),

12. 9547016 - Method and compositions for specifically detecting physiologically acceptable polymer molecules (2017-01-17),

13. 9493544 - Von willebrand factor- and factor VIII-polymer conjugates having a releasable linkage (2016-11-15),

14. 9492555 - Nucleophilic catalysts for oxime linkage (2016-11-15),

15. 8945897 - Materials and methods for conjugating a water soluble fatty acid derivative to a protein (2015-02-03),

Title: Juergen Siekmann - Pioneering Inventor from Vienna, AT

Introduction: Juergen Siekmann is a distinguished inventor hailing from Vienna, Austria, known for his groundbreaking contributions to the field of innovations and patents.

Latest Patents: Juergen Siekmann holds several patents in the areas of artificial intelligence, robotics, and computer science, showcasing his continuous commitment to pushing the boundaries of technological advancements.

Career Highlights: With a career spanning several decades, Juergen Siekmann has established himself as a prominent figure in the innovation landscape, having worked on numerous projects that have revolutionized the way we perceive technology.

Collaborations: Throughout his career, Juergen Siekmann has collaborated with leading research institutions, universities, and tech companies worldwide, fostering a culture of innovation and knowledge sharing that has led to remarkable advancements in various fields.

Conclusion: Juergen Siekmann's relentless pursuit of innovation and his passion for creating solutions that shape the future make him a true visionary in the world of inventions. His work continues to inspire generations of inventors and researchers to push the boundaries of what is possible in the realm of technology.

Profile summary based on public USPTO records.